publishers on the one hand and, and the federal government in the US.
And the pharmaceutical industry on the other hand,
in which they subpoenaed data from very large trials, and found out a lot of
side effects that would've been hidden, if the data had not been found.
So nowadays, we see the benefits, and
in medical sciences, it's a matter of life and death.
And in social science, it's a matter of good science.
In building, trying to grasp these social scientific topics,
which are very complex, very difficult, in which we try to build theories.
And if we only present the good results, we don't really builds.
[CROSSTALK]. >> We're never going to get there.
>> We don't, we don't know.
And if you, we all let people just do,
go around their business with the data, then, and we reward them for it.
Yeah, of course then people like Stapel will appear, reappear
>> Yep.
>> So you need to higher chances of, of problems and
scientific aspects, either be fraud or several of these biases in, in the system.
We need to deal with those.
And I think we were getting there but it's, it's fairly slow but in the end,
I hope that if I retire, that it will be much better than it is today.
>> That sounds like a, a positive note to end on.
>> Yeah.
Jelte, thank you very much.
I really appreciate it that you took the time to come here.
>> Yeah.
Thank you [CROSSTALK] Thanks for having me and good luck all.
>> Thank you.
[LAUGH]